More NewsRead More
Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300
January 07, 2015
Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma
January 06, 2015
Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients
December 23, 2014
Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
November 19, 2014
Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
November 10, 2014
Michael Grey Joins Mirati Therapeutics Board of Directors
November 06, 2014
11 Biotechnology Stocks to Buy Now
January 14, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here